Follow-up regimens for carriers of hereditary transthyretin variants.

doi:10.1016/j.medcli.2022.10.002

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Follow-up regimens for carriers of hereditary transthyretin variants.

Medicina clinica - 10 Mar 2023

Losada-López Inés Asunción, Kapetanovic-García Solange, Sevilla-Mantecón Teresa, Muñoz-Beamud Francisco

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Neuropathies, Familial
Share to Follow-Up Studies
Share to Heterozygote
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prealbumin

Source

Open in PubMed

Identifiers

PMID: 36529555
DOI: 10.1016/j.medcli.2022.10.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Follow-up regimens for carriers of hereditary transthyretin variants.PMID 36529555Read ↗

Transthyretin Genetic Testing.Semantic proximity Read ↗

Tabulation of transthyretin (TTR) variants as of 1/1/2000.Semantic proximity Read ↗

Tabulation of human transthyretin (TTR) variants, 2003.Semantic proximity Read ↗

Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter FutureSemantic proximity Read ↗

The role of transthyretin in cell biology: impact on human pathophysiologySemantic proximity Read ↗

Variation of tafamidis plasma levels during the treatment of TTR amyloidosis patients with Glu89Gln mutation.Semantic proximity Read ↗

Inability of mutant transthyretin V30M to cross the blood-eye barrier.Semantic proximity Read ↗

[Structural changes of transthyretin and its cytotoxicity].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.